Ozempic Cost 2026: What You'll Actually Pay
List price is $1,027.51 per 28-day supply, the same for every dose strength. Actual cost depends on insurance, program eligibility, and which dose you're on.
Ozempic list price is $1,027.51 per 28-day supply, uniform across all doses (0.25, 0.5, 1, and 2 mg). Commercial insurance covering Ozempic for type 2 diabetes brings the Savings Card rate as low as $25 per month. Uninsured patients new to the NovoCare Pharmacy offer pay $199 per month for the first 2 fills of 0.25 or 0.5 mg (valid through June 30, 2026), then $349 per month for 0.25 to 1 mg or $499 per month for 2 mg. Federal insurance plans (Medicare, Medicaid, Tricare, VA) are excluded from the Savings Card, though Medicare Part D generally covers Ozempic for type 2 diabetes with prior authorization. The Novo Nordisk Patient Assistance Program offers free Ozempic for income-qualified uninsured patients. Patients seeking semaglutide for weight loss should use Wegovy, which has better insurance coverage and a $149 per month oral pill option.
Looking for semaglutide for weight loss? Use Wegovy, not Ozempic.
Wegovy is the same molecule as Ozempic (semaglutide), FDA-approved for chronic weight management. Insurance coverage is better, and NovoCare Pharmacy offers a cash-pay pill at $149/month that Ozempic does not.
What you pay, by scenario
The four common payment paths. Every price assumes the prescription is for FDA-approved use (type 2 diabetes, CV risk reduction in T2D, or CKD progression in T2D).
Savings Card applies at retail pharmacy. Maximum savings $100 per 1-month, $200 per 2-month, or $300 per 3-month supply. FDA-approved use only.
NovoCare Pharmacy self-pay. $199 for first 2 fills of 0.25 or 0.5 mg (ends June 30, 2026), then $349/mo for 0.25-1 mg or $499/mo for 2 mg.
Federal plans excluded from the Savings Card. Medicare Part D generally covers Ozempic for type 2 diabetes. Medicaid varies by state. MFN framework expected to cap Medicare copays at approximately $50/mo mid-2026.
Novo Nordisk Patient Assistance Program offers free Ozempic for income-qualified uninsured patients. Apply at novocare.com. No registration or monthly fees.
NovoCare new-patient intro at $199/mo ends June 30, 2026
Uninsured patients new to the NovoCare Pharmacy offer can pay $199 per month for the first 2 fills of 0.25 mg or 0.5 mg Ozempic through June 30, 2026. After 2 fills or the end date (whichever comes first), pricing reverts to $349 per month. The 1 mg and 2 mg doses are not eligible for the $199 intro rate.
Ozempic self-pay price by dose
Cash-pay pricing through NovoCare Pharmacy. List price is uniform across all doses; the self-pay rate tiers by dose and new-patient status.
Recent pricing news
Self-pay program launch, federal pricing framework, and patent timeline.
- November 17, 2025
Uninsured / self-pay introductory pricing launched
Novo Nordisk launched a limited-time introductory offer for uninsured and self-pay patients: $199/month for the first 2 monthly fills of Ozempic 0.25 mg or 0.5 mg. Valid November 17, 2025 through June 30, 2026. After the intro period, pricing reverts to $349/month for 0.25-1 mg or $499/month for 2 mg.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Federal framework tying U.S. GLP-1 prices to lowest prices paid in comparable countries. Impact for Ozempic: Medicare Part D enrollees with type 2 diabetes coverage may see copays capped at approximately $50/month for eligible beneficiaries. Implementation in progress through 2026.
Status: Announced, implementation in progress.
- Invalid DateIn progress
Patent expiration (generic semaglutide eligibility)
Ozempic is patent-protected through 2031 per Novo Nordisk disclosures (per SingleCare reporting). Generic semaglutide cannot launch for Ozempic until the patent expires. No generic currently available or imminent.
Status: Anticipated. Monitor FDA approvals annually.
Related guides
Pricing verified against Novo Nordisk's official ozempic.com and novocare.com pages, cross-referenced with GoodRx, SingleCare, Optum Perks, and Weight Watchers. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.
